Chemotherapy for brain glioma has been of limited benefit due to the inability of drugs to
penetrate the blood–brain barrier (BBB) and non-selective drug accumulation in the entire …

Therapeutic outcome for the treatment of glioma was often limited due to the non-targeted
nature and low permeability of drugs across the blood-brain barrier (BBB). An ideal glioma …

The treatment of glioma is a great challenge because of the existence of the blood-brain
barrier (BBB). In order to reduce toxicity to the normal brain tissue and achieve efficient …

Gliomas are the most common malignant brain tumor, but treatment is limited by the blood–
brain barrier (BBB), especially for chemotherapeutic drugs. Although some chemotherapy …

Chemotherapy is an indispensable auxiliary treatment for glioma but highly limited by the
existence of both blood–brain barrier (BBB) and blood–brain tumor barrier (BBTB). The …

The abundant extracellular matrix (ECM) in the glioma microenvironment play a critical role
in the maintenance of glioma morphology, glioma cells differentiation and proliferation, but …

Background/Aim: Glioma is a deadly form of brain cancer. Doxorubicin is cytotoxic against
glioma cells. However, the blood-brain barrier (BBB) limits its ability to be delivered to the …

The development of a drug delivery strategy which can mediate efficient tumor targeting
together with high cellular internalization and extensive vascular extravasation is essential …

Low permeability across the blood–brain tumor barrier (BTB) and poor penetration into the
glioma parenchyma represent key obstacles for anti-glioblastoma drug delivery. In this …

Therapeutic effect of glioma is often limited due to low permeability of delivery systems
across the Blood-Brain Barrier (BBB) and poor penetration into the tumor tissue. In order to …